An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)

Trial Profile

An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs AZD 3409 (Primary)
  • Indications Hepatitis D
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 04 Aug 2016 Status changed from recruiting to discontinued.
    • 17 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top